Please login to the form below

Not currently logged in
Email:
Password:

ADA meeting

This page shows the latest ADA meeting news and features for those working in and with pharma, biotech and healthcare.

Novo says real-world data backs its insulin switching

Novo says real-world data backs its insulin switching

The Danish drugmaker reported findings from its EU-TREAT patient registry study at the American Diabetes Association (ADA) meeting in San Diego on Saturday. ... Top-line data from that trial was reported late last month and will be presented as a keynote

Latest news

  • IBM plans Watson-powered 'diabetes advisor' IBM plans Watson-powered 'diabetes advisor'

    The collaboration will marry IBM's Watson supercomputer with the vast repository of clinical and research data held by the ADA. ... Announcing the tie-up at the ADA's annual scientific meeting earlier this month, IBM and the ADA also outlined their plans

  • Rivals look to put pressure on Sanofi's Lantus Rivals look to put pressure on Sanofi's Lantus

    The American Diabetes Association's (ADA) Scientific Sessions meeting in Boston this weekend saw several of Sanofi's rivals claim clinical benefits over its blockbuster Lantus (insulin glargine). ... of patients reaching the ADA's target of HbA1c of less

  • Relief as study finds no cardiovascular risk with Januvia Relief as study finds no cardiovascular risk with Januvia

    The data will be scrutinised further when presented at the American Diabetes Association (ADA) meeting in Boston in June, but analysts suggested the results could help Januvia consolidate its position as

  • AZ and Takeda drugs should carry heart failure warning AZ and Takeda drugs should carry heart failure warning

    With that in mind, attention is fixed on the forthcoming results from the TECOS trial of Januvia, which are due to be presented at the American Diabetes Association (ADA) meeting in

  • AZ's Onglyza may increase mortality, says FDA AZ's Onglyza may increase mortality, says FDA

    AZ's Onglyza (saxagliptin) and Kombiglyze (saxagliptin plus metformin) will come under scrutiny at the meeting along with a similar drug Nesina (alogliptin) from Takeda. ... TECOS results are due to be presented at the American Diabetes Association (ADA)

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics